SCHEDULE: Fairmount Funds Reports 4.0% Stake in Astria Therapeutics
Beneficial Ownership Report
Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC filed an Amendment No. 7 to Schedule 13G, reporting a 4.0% beneficial ownership in Astria Therapeutics, Inc. common stock.
Summary
- Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC, as reporting persons, filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in Astria Therapeutics, Inc.
- The reporting persons, through Fairmount Healthcare Fund II LP ('Fund II'), beneficially own an aggregate of 2,377,049 shares of Astria Therapeutics, Inc. Common Stock.
- This ownership represents 4.0% of the Issuer's outstanding Common Stock.
- The 2,377,049 shares consist of 650,000 shares acquirable through Pre-Funded Warrants and 1,727,049 shares acquirable through common Warrants.
- The calculation of the 4.0% ownership is based on 58,811,943 shares of Common Stock outstanding as of October 14, 2025, which includes 56,434,894 shares outstanding as of July 31, 2025, plus the shares underlying the warrants owned by Fund II.
- The common warrants have an exercise price of $8.025 per share.
- A beneficial ownership limitation of 9.99% prevents the reporting persons from exercising warrants if, after exercise, their beneficial ownership would exceed this threshold.
Sentiment
Score: 5
Explanation: This is a routine beneficial ownership filing (Schedule 13G Amendment) and does not contain information that would typically indicate a positive or negative sentiment regarding the company's operational or financial performance. It merely updates the reported ownership stake of an institutional investor.
Risks
- A beneficial ownership limitation of 9.99% restricts the reporting persons from exercising their Pre-Funded Warrants or Warrants if such exercise would result in their aggregate beneficial ownership exceeding this percentage of the Issuer's outstanding Common Stock.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the stake held by a significant institutional investor, Fairmount Funds Management LLC, through its fund.
Key Dates
| Date | Description |
|---|---|
| 2021-12-31 | Original Schedule 13G filing date |
| 2021-09-22 | Amendment No. 1 filing date |
| 2021-06-17 | Amendment No. 2 filing date |
| 2023-02-14 | Amendment No. 3 filing date |
| 2024-02-14 | Amendment No. 4 filing date |
| 2024-11-14 | Amendment No. 5 filing date |
| 2025-02-14 | Amendment No. 6 filing date |
| 2025-07-31 | Date of Common Stock outstanding reported in the Company's most recent Quarterly Report on Form 10-Q |
| 2025-10-14 | Date of event which requires filing of this statement and date for calculation of total outstanding shares |
| 2025-10-15 | Filing date of Amendment No. 7 |
Keywords
Astria Therapeutics, Fairmount Funds Management, Fairmount Healthcare Fund II, Schedule 13G, beneficial ownership, common stock, warrants, pre-funded warrants, institutional ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.